The Evolving Healthcare Landscape and the Impact on Patient Access and Affordability
Medicare Part B: Do Providers Choose Treatment Based on Payment?
What does Medicare claims data reveal about physician-administered drugs? An Xcenda survey reveals whether physicians choose treatment based on how much they're reimbursed.
Xcenda Collaborated with MAPRx to Publish New Report Addressing Medicare Part D Challenges to Beneficiaries
Medicare Physician-Administered Drugs: Do Providers Choose Treatment Based on Payment Amount?
Japan’s Ongoing Shift From a Traditional Reimbursement Assessment to a Novel Cost-Effectiveness Submission Requirement
Taiwan: 10 Years of the Center for Drug Evaluation (CDE) Health Technology Assessment Division
How Policy Impacts Patient Support
What role does the changing healthcare coverage landscape play in support program demand and design?
How to Navigate Cell and Gene Therapy Reimbursement: Part One
An executive Q&A on challenges and opportunities related to reimbursement, coding and coverage for cell and gene therapies.
How to Navigate Cell and Gene Therapy Reimbursement: Part Two
An executive Q&A on the role of data and the future of innovative reimbursement modeling for cell and gene therapies.
Applying Cost-Effectiveness Thresholds to the Real World: Implications on Access for Medicare Beneficiaries
Rethink: Payer Strategies for Commercializing Cell and Gene Therapies
Insights from managed care executives on the future of coverage and outcomes evaluation.
Xcenda Examines the Impact of the Tax Cuts and Jobs Act on the Life Science Sector
Xcenda Collaborates with Family Reach on Critical Issue - Cancer-Related Financial Toxicity
What Do Payers Think About Digital Health Technologies
How are payers thinking about apps, wearables and other digital health technologies?
Medical Nutritional Therapy: Achieving Reimbursement Across the Globe for Unique Non-drug Therapy Options
Biologic Treatments for Severe Asthma—a Paradigm Shift From Targeted to More Personalized Medicine